SEARCH

SEARCH BY CITATION

References

  • 1
    Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: 2834.
  • 2
    Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 11371143.
  • 3
    Bizollon T, Ducerf C, Trepo C. Hepatitis C virus recurrence after liver transplantation. Gut 1999; 44: 575578.
  • 4
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Eng J Med 1996; 334: 815819.
  • 5
    Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317322.
  • 6
    Gretch DR, Bacchi CE, Corey L, delaRosa C, Lesniewski RR, Kowdley K, et al. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. Hepatology 1995; 22: 19.
  • 7
    Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619625.
  • 8
    Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8(suppl): 514518.
  • 9
    Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852858.
  • 10
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 11
    Berenguer M, Prieto M, Juan SJ, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 12
    Fisher L, Henley K, Lucey M. Acute cellular rejection after liver transplantation: Variability, morbidity, and mortality. Liver Transpl Surg 1995; 1: 1015.
  • 13
    Ben-Ari Z, Mor E, Sharharabani E, Bar-Nathan N, Shapira Z, Tur-Kaspa R. Combination of interferon-alpha and ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplant Proc 2000; 32: 714716.
  • 14
    Ghalib R, Pandula R, Kadhim TJ, Clark C, Ankoma-Sey V, Fouzia S, et al. Treatment of recurrent hepatitis C after liver transplantation with alpha-2B interferon plus ribavirin [Abstract]. Hepatology 2000; 32: 291A.
  • 15
    Willner IR, Chavin KD, Rogers J, Baliga P, Reuben A. Combination interferon-ribavirin is ineffective and poorly tolerated in liver transplant recipients with genotype 1 recurrent hepatitis C [Abstract]. Hepatology 2000; 32: 518A.
  • 16
    Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: Clinical and therapeutic issues. J Viral Hepatitis 2000; 7: 8792.
  • 17
    Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after transplantation: A nonrandomized trial of interferon alpha alone versus interferon alpha and ribavirin. Liver Transpl 2001; 7: 863869.
  • 18
    Neff G, Montalbano M, Lee Y, Slapak G, Safdar K, Morrero R. Naive treatment results in liver transplant recipients with hepatitis C virus recurrence (HCV-R) using pegylated interferon alpha-2B combined with ribavirin [Abstract]. Hepatology 2002; 36: 183A.
  • 19
    Gotz G, Schon MR, Haefker A, Neuhaus R, Berg T, Hopf U, et al. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin. Transplant Proc 1998; 30: 21042106.
  • 20
    Fisher L, Henley K, Lucey M. Acute cellular rejection after liver transplantation: Variability, morbidity, and mortality. Liver Transpl Surg 1995; 1: 1015.
  • 21
    Rhodes J, Jones DH, Bleehen MN. Increased expression of human monocyte HLA-DR antigens and Fc receptors in response to human interferon in vivo. Clin Exp Immunol 1983; 53: 739.
  • 22
    Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11: 13431353.
  • 23
    Baid S, Tolkoff-Rubin N, Saidman S, Chung R, Williams WW, Auchincloss H, et al. Brief communication acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74.
  • 24
    Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995; 22: 10841089.
  • 25
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431435.
  • 26
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 27
    Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658663.
  • 28
    Sheiner PA, Schwartz MA, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30.
  • 29
    Saab S, Busuttil W. Practical management of liver transplant recipients for hepatitis C. Minerva Chir 2003; 58: 479489.
  • 30
    Smith CM. Liver transplantation in the United States: A report from the UNOS Liver Transplant Registry. Clin Transpl 1999: 2334.
  • 31
    Ziolkowski J, Paczek L, Niewczas M, Senatorski G, Oldakowska-Jedynak U, Wyzgal J, et al. Acute liver transplant rejection: Incidence and the role of high-doses steroids. Transplant Proc 2003; 35: 22892291.
  • 32
    Mor E, Gonwa TA, Husberg BS, Goldstein RM, Klintmalm GB. Late-onset acute rejection in orthotopic liver transplantation—associated risk factors and outcome. Transplantation 1992; 10: 978985.
  • 33
    Anand AC, Hubscher SG, Gunson BK, McMaster P, Neuberger JM. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 1995; 60: 10981103.
  • 34
    Andreu H, Rimola A, Bruguera M, Navasa M, Cirera I, Grande L, et al. Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: Predictive factors of response to antirejection therapy. Transplantation 2002; 73: 19361943.
  • 35
    Ramji A, Yoshida EM, Bain VG, Kneteman NM, Scudamore CH, Ma MM, et al. Late acute rejection after liver transplantation: The Western Canada Experience. Liver Transpl 2002; 8: 945951.
  • 36
    Kornberg A, Hommann M, Tannapfel A, Wagner T, Grube T, Schotte U, et al. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients. Am J Transplant 2001; 1: 350.
  • 37
    Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 10681070.
  • 38
    Ahmad J, Dodson SF, Demetrius AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: A randomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001; 7: 863869.
  • 39
    Bizollon T, Ducerf C, Trepo C, Mutimer D. Hepatitis C virus recurrence after liver transplantation. Gut 1999; 44: 575578.
  • 40
    Fischer L, Sterneck M, Valentin-Gamazo G, Feucht HH, Malago M, Broelsch CE. Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha. Transplant Proc 1999; 31: 494495.
  • 41
    Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon and ribavirin. Liver Transpl 2001; 7: 181190.
  • 42
    Vargas V, Charco R, Castells R, Esteban R, Margarit C. Alpha-interferon for acute hepatitis C in liver transplant patients. Transplant Proc 1995; 27: 12221223.
  • 43
    Wright T, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773779.
  • 44
    Wright H, Gavaler J, Van Thiel D. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53: 121124.
  • 45
    Jain A, Demetris AJ, Manez R, Tsamanadas AC, Van Thiel D, Rakela J, et al. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg 1998; 4: 197203.
  • 46
    Kovarik J, Mayer G, Pohanka E, Schwarz M, Traindl O, Graf H, et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988; 45: 402405.
  • 47
    Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989990.
  • 48
    Hirsch MS, Schooley RT, Cosimi AB, Russell PS, Delmonico FL, Tolkoff-Rubin NE, et al. Effects of interferon-alpha on cytomegalovirus reactivation syndrome in renal transplant recipients. N Eng J Med 1983; 308: 14891493.
  • 49
    Gubernatis G, Kemnitz J, Tusch G, Pichlmayer R. HLA compatibility and different features of liver allograft rejection. Transpl Int 1988; 1: 155160.
  • 50
    Mor E, Solomon H, Gibbs J, Holman MJ, Goldstein RM, Husberg BS, et al. Acute cellular rejection following liver transplantation: Clinical pathologic features and effect on outcome. Semin Liver Dis 1992; 12: 2840.
  • 51
    Slater AD, Klein JB, Sonnenfeld G, Ogden LL II, Gray LA Jr. The effects of interferon-alpha/beta in a model of rat heart transplantation. J Heart Lung Transplant 1992; 11: 975978.
  • 52
    Steinhoff G, Wonigeit K, Oichlmayer R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45: 394401.
  • 53
    Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994; 330: 11601161.
  • 54
    Dumortier J, Scoazec J, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2B and ribavirin. [Abstracts]. Hepatology 2003; 34: 535A.
  • 55
    Samuel D, Brousse, P. Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon and ribavirin. [Abstracts]. Hepatology 2003; 34: 531A.
  • 56
    Kugelmas M, Osgood M, Trotter J, Bak T, Wachs M, Forman L, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003; 9: 11591165.
  • 57
    Thervet E, Pol S, Legendre MF, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994; 58: 625627.
  • 58
    Ambrus JL, Chadka KC, Anthone S, Anthone R, Sayyid S. The alpha-interferon system in patients undergoing renal transplantation and treated with cyclosporine and prednisone. Surg Gynecol Obstet 1993; 176: 588590.
  • 59
    Potter C, Phair JP, Vodinelich L, Fenton R, Jennings R. Antiviral, immunosuppressive and antitumour effects of ribavirin. Nature 1976; 259: 496497.
  • 60
    Gottschlich MJ, Aardema KL, Burd EM, Nakhleh RE, Brown KA, Abouljoud MS, et al. The use of hepatitis C viral RNA levels in liver tissue to distinguish rejection from recurrent hepatitis C. Liver Transpl 2001; 7: 436441.
  • 61
    Doughty AL, Zekry A, Spencer JD, Turhan S, Painter D, McCaughan GW. Spontaneous clearance of hepatitis C virus infection post-liver transplantation is associated with rapidly changing quasispecies: A single case report. Liver Transpl 2000; 6: 648653.
  • 62
    Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384393.